Research in the Department of Neuro-Oncology focuses on extending our understanding of the genetic abnormalities and molecular events responsible for the development, progression and spread of brain tumors. By translating laboratory findings into new treatments, we can offer more effective therapies and improve survival rates and quality of life for brain tumor patients.
We employ researchers recognized for their expertise in the areas implicated in the development and progression of central nervous system tumors. These researchers work closely with physician-scientists to integrate laboratory discoveries and clinical observations into treatment innovations.
In addition, our researchers participate in multi-institutional research efforts, collaborating with world-renowned brain tumor treatment programs such as CERN and BTTC.
Read more detailed information about research in neuro-oncology.
The CERN (Collaborative Ependymoma Research Network) Foundation is a non-profit organization whose mission is to develop new treatments for ependymoma, a rare type of primary brain or spinal cord tumor, and improve the outcomes and care of patients, ultimately leading to a cure. CERN and MD Anderson have a unique collaboration, working together on research, clinical trials and treatments.
With the ultimate goal of finding a cure, the Brain Tumor Trials Collaborative (BTTC) is a network of multiple medical centers around the country that participate in state-of-the-art research and clinical trials for malignant brain tumors. MD Anderson leads the research collaboration.